AgomAb Therapeutics

AGMBNasdaq Belgium Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$576.201 M

$11.70 -3.86%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

34,167,168

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#60Allogene TherapeuticsALLO$583.9M
#61Prime MedicinePRME$578.6M
#62AgomAb TherapeuticsAGMB$576.2M
#63ProkidneyPROK$536.6M
#64Scribe TherapeuticsSCTX$531.0M

What if AgomAb Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$614,726.88

Per share 52,541× higher

Bitcoin $1.72T

$34,921.31

Per share 2,985× higher

Nvidia $5.48T

$111,270.73

Per share 9,510× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for AgomAb Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.